Inventiva to Participate in the "ROTH Battle of the NASH Thrones Investor Conference"
Daix (France), October 12, 2018 - Inventiva S.A. ("Inventiva" or the "Company"), a biopharmaceutical company developing innovative therapies in nonalcoholic steatohepatitis (NASH), systemic sclerosis (SSc) and mucopolysaccharidosis (MPS), today announced that Pierre Broqua, Chief Scientific Officer and co-founder of Inventiva, will participate in the upcoming "ROTH Battle of the NASH Thrones Investor Conference" being held on October 17, 2018 at the Park Hyatt New York hotel, New York, USA.
Pierre Broqua will be speaking in the panel entitled "House of PPARs vs. House of THR-beta", one of the conference's four panel discussions covering topics currently at the forefront of drug development in NASH.
The event details are as follows:
Panel: "House of PPARs vs. House of THR-beta"
Date: Wednesday, October 17, 2018
Time: 12:00 pm - 1:00 pm (Eastern Time)
Location: Park Hyatt New York hotel, 153 West 57th St., New York, NY 10019, USA
About Inventiva: www.inventivapharma.com (http://www.inventivapharma.com)
Inventiva is a biopharmaceutical company specialized in the development of drugs interacting with nuclear receptors, transcription factors and epigenetic modulators. Inventiva's research engine opens up novel breakthrough therapies against fibrotic diseases, cancers and orphan diseases with substantial unmet medical needs.
Lanifibranor, its lead product, is an anti-fibrotic treatment acting on the three alpha, gamma and delta PPARs (peroxisome proliferator-activated receptors), which play key roles in controlling the fibrotic process. Its anti-fibrotic action targets two initial indications with substantial unmet medical need: NASH, a severe and increasingly prevalent liver disease already affecting over 30 million people in the United States, and systemic sclerosis, a disease with a very high mortality rate and for which there is no approved treatment to date.
Inventiva is also developing a second clinical program with odiparcil (IVA 336) for the treatment of patients with mucopolysaccaridosis type VI (or Maroteaux-Lamy syndrome), a rare and severe gene disease affecting children. Odiparcil has also the potential to address other MPS types, characterized by the accumulation of chondroitin or dermatan sulfate (MPS I or Hurler/Sheie syndrome, MPS II or Hunter syndrome, MPS IVa or Morquio syndrome and MPS VII or Sly syndrome). Inventiva is also developing a portfolio of early research projects in the field of oncology.
Inventiva benefits from partnerships with world-leading research entities such as the Institut Curie in the field of oncology. Two strategic partnerships have also been established with world-class major pharmaceutical companies AbbVie and Boehringer Ingelheim in the fields of autoimmune diseases (specifically in psoriasis) and fibrosis respectively. These partnerships provide milestone payments to Inventiva upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on the products resulting from the partnerships.
Inventiva employs over 100 highly qualified employees and owns state-of-the-art R&D facilities near Dijon, acquired from the international pharmaceutical group Abbott. The Company owns, a proprietary chemical library of over 240,000 molecules as well as integrated biology, chemistry, ADME and pharmacology platforms.
Contacts
| Inventiva Frédéric Cren Chairman & CEO info@inventivapharma.com (mailto:info@inventivapharma.com) +33 3 80 44 75 00 | Brunswick Julien Trosdorf / Yannick Tetzlaff Media relations inventiva@brunswickgroup.com (mailto:inventiva@brunswickgroup.com) +33 1 53 96 83 83 | LifeSci Advisors Monique Kosse Investor relations monique@lifesciadvisors.com (mailto:monique@lifesciadvisors.com) +1 212 915 3820 |
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: INVENTIVA via Globenewswire
